Advertisement

Evidence that spiperone reverses the additional sympathoinhibitory action of urapidil in anaesthetised, prazosin-pretreated cats

  • Andrew G. Ramage
Chapter
Part of the Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine book series (DICM, volume 106)

Abstract

Urapidil is a novel antihypertensive agent which lowers blood pressure by decreasing total peripheral resistance and also reduces central sympathetic outflow [1–3]. As urapidil blocks α1 -adrenoceptors, this profile of action is what would be expected from such a drug. However, many authors have been unable to relate the central sympathoinhibitory effect of urapidil to its α1-adrenoceptor blocking action [3]. It has been suggested that urapidil could also be acting on 5-HT1A receptors [3] and the ability of urapidil to bind to these receptors [4] supports such a hypothesis, However, using the intravertebral route of administration [5] (giving drugs via the vertebral artery) (–)pindolol, which attenuated the hypotensive action of several putative 5-HT1A receptor agonists, did not influence the hypotensive response to urapidil. This suggests that the central hypotensive action of urapidil is not related to an agonist action at 5-HT1A receptors but it is possible that the α1-adrenoceptor antagonist action of urapidil is masking this inhibition, and/ or (–) pindolol may not be the ‘ideal’ antagonist. The present experiments were designed to overcome these problems by, first, pretreating the animals with a large dose of prazosin to ensure complete α 1-adrenoceptor blockade and by using spiperone as the antagonist as spiperone has been reported to reverse the sympathoinhibitory action of 8-OH-DPAT [6].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schoetensack W, Bischler P, Ditterman E Ch, Steinijans V (1977): Tierexperimentelle Untersuchungen uber den Einfluss des Antihypertensivums Urapidil auf den Kreislauf und die Kreislaufregulation. Arzneim Forsch Drug Res 27: 1908–1919.Google Scholar
  2. 2.
    Sanders KH, Jurna I (1985): Effects of urapidil, clonidine, prazosin and propranolol on autonomic nerve activity and heart rate in anaesthetised rat and cat. Eur J Pharmac 110: 181–190.CrossRefGoogle Scholar
  3. 3.
    Ramage AG (1986): A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats. Eur J Pharmac 129: 307–314.CrossRefGoogle Scholar
  4. 4.
    Fozard JR, Mir AK (1987): Are 5-HT receptors involved in the hypotensive effects of urapidil? Br J Pharmac 90: 24 P.Google Scholar
  5. 5.
    Doods HN, Boddeke WG, Kalkman HD, Hoyer D, Mathy MJ, Van Zwieten PA (1988): Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+) 8-OH-DPAT, DP-5-CT, R28935 and urapidil. J Cardiovasc Pharmac 11: 432–438.CrossRefGoogle Scholar
  6. 6.
    McCall RB, Patel BN, Harris LT (1987): Effects of serotonin, and serotonin2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmac Exp Ther 242: 1152–1159.Google Scholar
  7. 7.
    Ramage AG (1988): Are drugs that act both on serotonin receptors and α1-adrenoceptors more potent hypotensive agents than those that act only on α1-adrenoceptors? J Cardiovasc Pharmac 11 (suppl. 1): S30–S34.CrossRefGoogle Scholar
  8. 8.
    Leysen JE (1985): Serotonergic binding sites, pp. 43–62 in: Vanhoutte PM (ed), Serotonin and the Cardiovascular System. New York: Raven Press.Google Scholar
  9. 9.
    Gillis RA, Kellar KJ, Quest JA, Namath IJ, Martino-Barrows A, Hill K, Gratti PJ, Dretchen K (1988): Experimental studies on the Neurocardiovascular effects of urapidil. Drugs 35 (Suppl. 6): 20–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Groß G, Hanft G, Kolassa N (1987): Urapidil and some analogues with hypotensive properties show high affinity for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for a1-adrenoceptor binding sites. Naunyn-Schmiedebergs Arch Pharmac 336: 597–601.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1990

Authors and Affiliations

  • Andrew G. Ramage

There are no affiliations available

Personalised recommendations